辰欣药业股份有限公司关于持股5%以上股东减持股份计划完成暨减持股份结果公告

Group 1 - The major shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., held 27,661,441 shares of Chenxin Pharmaceutical, accounting for 6.11% of the total share capital before the reduction plan [2] - The reduction plan was disclosed on August 30, 2025, with a maximum reduction of 4,527,000 shares, representing 1.00% of the total shares [3] - As of September 24, 2025, the major shareholder had reduced its holdings by 4,520,000 shares, bringing the total shareholding down to 26,661,441 shares, which is 5.89% of the total [3][5] Group 2 - The reduction plan was fully implemented, and the actual reduction matched the previously disclosed plan [5] - There were no concerted actions among the major shareholder [4] - The reduction was completed within the specified time frame without any early termination of the plan [5]